Targeting von Willebrand Factor in Ischaemic Stroke: Focus on Clinical Evidence

Despite great efforts in stroke research, disability and recurrence rates in ischaemic stroke remain unacceptably high. To address this issue, one potential target for novel therapeutics is the glycoprotein von Willebrand factor (vWF), which increases in thrombogenicity especially under high shear r...

Descripción completa

Detalles Bibliográficos
Autores principales: Buchtele, Nina, Schwameis, Michael, Gilbert, James C., Schörgenhofer, Christian, Jilma, Bernd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Schattauer GmbH 2018
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193403/
https://www.ncbi.nlm.nih.gov/pubmed/29847840
http://dx.doi.org/10.1055/s-0038-1648251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193403/
https://www.ncbi.nlm.nih.gov/pubmed/29847840
http://dx.doi.org/10.1055/s-0038-1648251

Ejemplares similares